Discover how mirdametinib, a next-generation MEK1/2 inhibitor originally developed for MAPK-driven tumors, is emerging as a promising tool to modulate ERK signaling, improve synaptic plasticity, and potentially treat treatment-resistant depression beyond traditional monoamine-based antidepressants.
Discover how NTRX-07, a first-in-class small molecule targeting microglial activity, offers a novel immunology-based strategy for Alzheimer’s disease by reducing neuroinflammation, enhancing amyloid-β clearance, and promoting neuroprotective repair pathways.